These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Balancing the benefits and costs of antibiotic drugs: the TREAT model. Leibovici L; Paul M; Andreassen S Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community]. Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168 [TBL] [Abstract][Full Text] [Related]
4. It is money that matters: decision analysis and cost-effectiveness analysis. Kocher MS; Henley MB Clin Orthop Relat Res; 2003 Aug; (413):106-16. PubMed ID: 12897601 [TBL] [Abstract][Full Text] [Related]
5. [Decision analysis and initiation of an "empiric" therapy]. Van Meerhaeghe A Rev Med Brux; 1999 Feb; 20(1):21-4. PubMed ID: 10091532 [TBL] [Abstract][Full Text] [Related]
6. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. Das A Am J Gastroenterol; 1998 Oct; 93(10):1895-900. PubMed ID: 9772051 [TBL] [Abstract][Full Text] [Related]
7. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I. Kusowska J Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989 [TBL] [Abstract][Full Text] [Related]
8. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II. Kusowska J Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990 [TBL] [Abstract][Full Text] [Related]
9. Is antibiotic prophylaxis for bacterial endocarditis cost-effective? Agha Z; Lofgren RP; VanRuiswyk JV Med Decis Making; 2005; 25(3):308-20. PubMed ID: 15951458 [TBL] [Abstract][Full Text] [Related]
10. The TREAT project: decision support and prediction using causal probabilistic networks. Leibovici L; Paul M; Nielsen AD; Tacconelli E; Andreassen S Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S93-102. PubMed ID: 17890063 [TBL] [Abstract][Full Text] [Related]
11. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Elting LS; Cantor SB Support Care Cancer; 2002 Apr; 10(3):189-96. PubMed ID: 11904783 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic therapy 1985: what are the challenges? Cohen MS Hosp Formul; 1985 Dec; 20(12):1247-8. PubMed ID: 10311346 [TBL] [Abstract][Full Text] [Related]
13. [The other side of the coin: socioeconomic analysis of antibiotic resistance]. García-Altés A; Jovell AJ; Aymerich M Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():27-31. PubMed ID: 10605187 [TBL] [Abstract][Full Text] [Related]
14. Empirical treatment of bacteraemic urinary tract infection. Evaluation of a decision support system. Kristensen B; Andreassen S; Leibovici L; Riekehr C; Kjaer AG; Schønheyder HC Dan Med Bull; 1999 Sep; 46(4):349-53. PubMed ID: 10514942 [TBL] [Abstract][Full Text] [Related]
15. [Health economics and antibiotic therapy]. Leclercq P; Bigdéli M Rev Med Brux; 1995; 16(4):320-4. PubMed ID: 7481251 [TBL] [Abstract][Full Text] [Related]
16. [Decision analytic modeling and their impact on health care decision making]. Inotai A; Kaló Z; Mészáros A Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of intracameral cefuroxime use for prophylaxis of endophthalmitis after cataract surgery. Sharifi E; Porco TC; Naseri A Ophthalmology; 2009 Oct; 116(10):1887-96.e1. PubMed ID: 19560825 [TBL] [Abstract][Full Text] [Related]
19. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. Vanness DJ; Kim WR Health Econ; 2002 Sep; 11(6):551-66. PubMed ID: 12203757 [TBL] [Abstract][Full Text] [Related]
20. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Deresinski S Clin Infect Dis; 2007 Sep; 45 Suppl 3():S177-83. PubMed ID: 17712744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]